WP1066 plus radiation for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of glioblastoma confirmed by pathology, and it is IDH “wild-type”
- Your tumor test shows MGMT is “unmethylated” (based on lab testing)
- You must be at least 18 years old and able to do the study tasks and visits (Karnofsky score 60% or higher)
- You must be able to start study treatment within 8 weeks after your initial brain surgery (biopsy or resection)
- Blood counts and organ tests must be within required ranges (white cells, neutrophils, platelets, liver tests, kidney function, and blood clotting tests)
- You must be able to get a brain MRI with contrast dye, and you must agree to birth-control rules if pregnancy is possible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
This trial tests a new way of giving radiation therapy (pulsed) compared to standard radiation for people with a specific type of glioblastoma (IDH wildtype, MGMT unmethylated). The goal is to see if the pulsed approach helps with thinking and memory while still treating the tumor.
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.